SCHEMBL42643

SCHEMBL42643

CN(C)c1ccc(/N=N/c2ccc(S(N)(=O)=O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 1.00
CA12 O43570 8/20 1.00
CA9 Q16790 8/20 1.00
MEN1 O00255 1/20 1.00
NPC1 O15118 1/20 1.00
POLB P06746 1/20 1.00
RAB9A P51151 1/20 1.00
KMT2A Q03164 1/20 1.00
PTGS2 P35354 4/20 0.67
CA1 P00915 4/20 0.67
PTGS1 P23219 2/20 0.67
LMNA P02545 1/20 0.66
F2 P00734 3/20 0.64
PRSS1 P07477 3/20 0.64
PRSS2 P07478 3/20 0.64
PRSS3 P35030 3/20 0.64
CA7 P43166 2/20 0.59
ALDH1A1 P00352 2/20 0.59
TSHR P16473 2/20 0.59
ALOX15 P16050 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42659 1.00 CA2 (1.00) CA2CA12CA9MEN1NPC1
SCHEMBL330045 0.88 CA2 (0.78) CA2CA12CA9MEN1NPC1
SCHEMBL15631068 0.85 NPC1 (0.73) CA2CA12CA9MEN1NPC1
SCHEMBL9019288 0.83 NPC1 (0.71) CA2CA12CA9MEN1NPC1
SCHEMBL13602555 0.83 NPC1 (0.71) CA2CA12CA9MEN1NPC1
SCHEMBL14419936 0.83 NPC1 (0.71) CA2CA12CA9MEN1NPC1
SCHEMBL13384871 0.83 NPC1 (0.71) CA2CA12CA9MEN1NPC1
SCHEMBL8492321 0.82 CA2 (0.70) CA2CA12CA9MEN1NPC1
SCHEMBL42344 0.81 NPC1 (0.69) CA2CA12CA9MEN1NPC1
Methyl Orange SCHEMBL296471 0.81 NPC1 (0.69) CA2CA12CA9MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240123045-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2024-04-18 US claimed
EP-4297874-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2024-01-03 EP claimed
US-11780863-B2 Quinone methide analog signal amplification VENTANA MEDICAL SYSTEMS, INC. (US) 2023-10-10 US claimed
EP-3377530-B1 METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUE VENTANA MED SYST INC (US) 2021-06-30 EP claimed
US-20200271662-A1 PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER VENTANA MED SYST INC (US) 2020-08-27 US claimed
EP-2686438-B1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR VENTANA MED SYST INC (US) 2018-04-18 EP claimed
EP-2686438-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE Ventana Medical Systems, Inc. (US) 2014-01-22 EP claimed
EP-2539355-A1 POLYTAG PROBES Ventana Medical Systems, Inc. (US) 2013-01-02 EP claimed
EP-2539466-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES Ventana Medical Systems, Inc. (US) 2013-01-02 EP claimed
US-20120301886-A1 POLYTAG PROBES VENTANA MEDICAL SYSTEMS, INC. 2012-11-29 US claimed
US-20120301885-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES TANG LEI (US) 2012-11-29 US claimed
US-20120237930-A1 METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE VENTANA MEDICAL SYSTEMS, INC. 2012-09-20 US claimed
WO-2012123387-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO claimed
WO-2011106495-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES VENTANA MEDICAL SYSTEMS, INC. (US) 2011-09-01 WO claimed
WO-2011106583-A1 POLYTAG PROBES VENTANA MEDICAL SYSTEMS, INC. (US) 2011-09-01 WO claimed
US-20240123045-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2024-04-18 US disclosed
US-20240069034-A1 PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER VENTANA MED SYST INC (US) 2024-02-29 US disclosed
WO-2008063378-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MEDICAL SYSTEMS, INC. (US) 2008-05-29 WO disclosed
EP-0877616-A1 MEDICAMENTS CONTAINING AROMATIC AZO COMPOUNDS Roche Diagnostics GmbH (DE) 1998-11-18 EP disclosed
WO-1997026890-A1 MEDICAMENTS CONTAINING AROMATIC AZO COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1997-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780863-B2 Quinone methide analog signal amplification NQO2, SQOR, MRM1 CA2 2563/4885CA12 1792/4885CA9 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.